EGFR and breast cancer: In this sense, a randomized trial of paclitaxel with lapatinib versus placebo as first line treatment in metastatic BC noticed that paclitaxel with lapatinib has not shown an overall efficacy in TNBC, suggesting that EGFR tyrosine kinase activity may not be the major vulnerability in this subtype [84].